Only a few studies have reported a long-term follow-up in a significant number of patients using continuous subcutaneous insulin infusion (CSII) (1). Who stands to benefit more from this costly insulin therapy is still unclear. The aim of our observational, retrospective study was to evaluate the possible predictors of the degree of improvement of metabolic control with CSII in 82 consecutive type 1 diabetic patients (age 37.9 ± 13.4 years, 42 men and 40 women, duration of diabetes 19.7 ± 9.9 years) who started CSII in the Diabetes Unit of Bergamo Hospital between June 1999 and March 2004. The patients had been treated with multiple daily injection (MDI) therapy (regular [ n = 22] or rapid-acting analog insulin [ n = 60] before meals plus NPH [ n = 72] or glargine [ n = 10] as basal insulin) for at least 1 year. During CSII treatment, lispro or aspart analogs were used. All patients were evaluated …
No takes yet. Share an insight, caveat, or question.
Lepore et al. (2005) studied this question.